Heart Failure | Unmet Need | Acute Heart Failure | US/EU | 2020
Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. This study evaluates how current therapies are differentiated based on their performance on key drug attributes and measures the impact of these attributes on the prescribing behavior of cardiologists. Revealing the relative importance of unmet needs helps identify the most attractive opportunities in AHF treatment.
QUESTIONS ANSWERED
- Which drug attributes most strongly influence AHF drug selection?
- How do cardiologists rate key current AHF therapies across select drug attributes?
- Where are the hidden opportunities for drug development in the AHF therapy market?
- Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of AHF?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 32 European cardiologists fielded in December 2019.
Key companies: Novartis, Johnson & Johnson, Pfizer.
Key drugs: Nitrate vasodilators, loop diuretics, inotropic sympathomimetics, PDE3 inhibitors, calcium sensitizers.
